June 24–28, 2011 – San Diego Convention Center
The Immune Tolerance Network is conducting a portfolio of innovative intervention research trials in new-onset type 1 diabetes.
Join us for the following preliminary trial result presentations:
Tuesday, June 28th
AbATE Study (hOKT3γ1(Ala-Ala); teplizumab), by Kevan Herold, MD and Stephen Gitelman, MD.
Monday, June 27th
Rapamycin plus IL-2 combination therapy in subjects with T1D results in a sustained increase in IL-2 responsiveness and a transient decrease in C-peptide levels, by Carla Greenbaum, MD
Visit Us at 71st Scientific Sessions Booth #2648 and
Learn More About Our Type 1 Diabetes Clinical Trials
More Information
Directions to the San Diego Convention center.
More details regarding the 71st Scientific Sessions (2011).
Learn about ITN type 1 diabetes trials currently underway:
 | Research Trial of Aralast NP in New-onset Type 1 Diabetes: www.retainstudy.org |
 | Inducing Remission in New-onset Type 1 Diabetes with Alefacept: www.t1dal.org |